Organogenesis (NASDAQ:ORGO) Rating Lowered to Sell at Zacks Investment Research – Defense World

Organogenesis (NASDAQ:ORGO Get Rating) was downgraded by Zacks Investment Research from a hold rating to a sell rating in a research report issued to clients and investors on Saturday, Zacks.com reports.

According to Zacks, Organogenesis is a leading regenerative medicine company focused on the development, manufacture and commercialization of solutions for the Advanced Wound Care and Surgical & Sports Medicine markets.

Shares of ORGO stock opened at $6.17 on Friday. The stock has a market cap of $796.39 million, a P/E ratio of 9.79 and a beta of 1.72. Organogenesis has a one year low of $5.30 and a one year high of $19.75. The stock has a fifty day moving average price of $7.26 and a 200 day moving average price of $8.40. The company has a debt-to-equity ratio of 0.29, a current ratio of 2.77 and a quick ratio of 2.46.

In other Organogenesis news, VP Antonio S. Montecalvo sold 97,436 shares of Organogenesis stock in a transaction on Thursday, March 10th. The stock was sold at an average price of $8.39, for a total transaction of $817,488.04. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. 34.20% of the stock is currently owned by company insiders.

Several hedge funds and other institutional investors have recently modified their holdings of ORGO. Morgan Stanley increased its stake in shares of Organogenesis by 2,249.9% in the second quarter. Morgan Stanley now owns 1,849,596 shares of the companys stock valued at $30,741,000 after buying an additional 1,770,888 shares in the last quarter. BlackRock Inc. increased its stake in shares of Organogenesis by 17.1% in the first quarter. BlackRock Inc. now owns 9,652,188 shares of the companys stock valued at $73,551,000 after buying an additional 1,412,356 shares in the last quarter. Soleus Capital Management L.P. increased its stake in shares of Organogenesis by 212.4% in the fourth quarter. Soleus Capital Management L.P. now owns 1,999,087 shares of the companys stock valued at $18,472,000 after buying an additional 1,359,200 shares in the last quarter. State Street Corp increased its stake in shares of Organogenesis by 33.0% in the fourth quarter. State Street Corp now owns 5,400,860 shares of the companys stock valued at $49,904,000 after buying an additional 1,341,450 shares in the last quarter. Finally, Macquarie Group Ltd. acquired a new stake in shares of Organogenesis in the third quarter valued at $17,647,000. 38.41% of the stock is owned by institutional investors.

Organogenesis Company Profile (Get Rating)

Organogenesis Holdings Inc, a regenerative medicine company develops, manufactures, and commercializes solutions for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care products include Affinity, an amniotic membrane wound covering in which viable cells growth factors/cytokines, and ECM proteins in the native tissue are preserved; Apligraf, a bioengineered living cell therapy that produce spectrum of cytokines and growth factors; Dermagraft, a bioengineered product that produces human collagen, ECM, proteins, and cytokines; NuShield, a wound covering tissue includes both amnion and chorion membranes for spongy/intermediate layer intact; PuraPly , a antimicrobial barrier that enables conformability and fluid drainage; and Novachor, an amniotic membrane wound covering in which viable cells, growth factors/cytokines, and ECM proteins are preserved.

Organogenesis (NASDAQ:ORGO) Rating Lowered to Sell at Zacks Investment Research – Defense World

Categories

Archives

Recommended Sites

Contact Us

Recent Posts